Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
2.440
0.00 (0.00%)
At close: Nov 22, 2024, 4:00 PM
2.510
+0.070 (2.87%)
After-hours: Nov 22, 2024, 6:13 PM EST
Palisade Bio Employees
Palisade Bio had 9 employees as of December 31, 2023. The number of employees decreased by 3 or -25.00% compared to the previous year.
Employees
9
Change (1Y)
-3
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,562,778
Market Cap
3.24M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9 | -3 | -25.00% |
| Dec 31, 2022 | 12 | -1 | -7.69% |
| Dec 31, 2021 | 13 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Matinas BioPharma Holdings | 32 |
| Oncternal Therapeutics | 30 |
| NovaBay Pharmaceuticals | 26 |
| Theriva Biologics | 22 |
| InMed Pharmaceuticals | 13 |
| Revelation Biosciences | 9 |
| SCWorx | 7 |
| Enveric Biosciences | 7 |
PALI News
- 1 day ago - Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC) - GlobeNewsWire
- 10 days ago - Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108 - GlobeNewsWire
- 22 days ago - Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis - GlobeNewsWire
- 6 weeks ago - Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC) - GlobeNewsWire
- 3 months ago - Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis - GlobeNewsWire
- 4 months ago - Palisade Bio Participates in Virtual Investor “What this Means” Segment - GlobeNewsWire
- 4 months ago - Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108 - GlobeNewsWire